Inhibiting ERK5 Overcomes Breast Cancer Resistance to Anti-HER2 Therapy By Targeting the G1-S Cell-Cycle Transition (2022)
Attributed to:
The University of Manchester (UoM) bid for phase 7 of MRC Confidence in Concept (CiC) funding
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1158/2767-9764.crc-21-0089
PubMed Identifier: 36466034
Publication URI: http://europepmc.org/abstract/MED/36466034
Type: Journal Article/Review
Parent Publication: Cancer Research Communications
Issue: 3
ISSN: 2767-9764